Moleculin: MIRACLE trial unblinding on track for Q1 2026; global expansion to 9 countries

Moleculin Biotech, Inc.

First unblinding of 45 subjects in pivotal Phase 2B/3 MIRACLE trial for 2L AML expected Q1 2026.
Trial expanded to 9 countries with over 46 sites selected; next unblinding of 90 subjects expected Q3 2026.
Atlantic Health to fund IIT with Annamycin in 3L pancreatic cancer; preclinical data show activity.
WP1066 Phase 2 GBM trial at Northwestern continues; Emory to start pediatric brain tumor trial in 2H 2026.
Non-cardiotoxicity review of Annamycin data to be presented Q1 2026; potential first non-cardiotoxic anthracycline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.